China begins human trial on another potential Covid-19 antibody therapy | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
May 31, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, MAY 31, 2025
China begins human trial on another potential Covid-19 antibody therapy

Coronavirus chronicle

TBS Report
09 June, 2020, 09:15 pm
Last modified: 09 June, 2020, 09:19 pm

Related News

  • Children have stronger antibody response to Covid: Study
  • Covid-19 antibody surveys underestimate infections: Study
  • Preliminary results show Chinese Covid-19 vaccine candidate safe
  • Antibody drugs are no cure but seem promising for Covid-19
  • US warns of fraudulent coronavirus antibody tests

China begins human trial on another potential Covid-19 antibody therapy

There are several other companies trying to create antibody therapies to fight Covid-19, including Regeneron Pharmaceuticals, which has said it expects to begin clinical trials this month

TBS Report
09 June, 2020, 09:15 pm
Last modified: 09 June, 2020, 09:19 pm
China begins human trial on another potential Covid-19 antibody therapy

An antibody treatment developed by Eli Lilly and Chinese company Junshi Biosciences to fight Covid-19 was dosed to a healthy volunteer on Monday.

The trial is underway in China, Lilly will start a complementary Phase one study in the United States in the next few days, the company said, reports the CNN.

Scientists will first test to see if this antibody treatment, called JS016, is safe to be used in humans. If so, it will be tested to see if it if effective. 

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

If this first phase is successful, more trials will run to determine how to use it most effectively. 

The companies will also experiment to see if the antibody could be used on its own or if it would be more effective used in combination with other antibody candidates. JS016 appeared to neutralize the virus in the lab. Lilly and Junshi scientists are testing other potential antibodies in the lab to see which work best. 

This is the second such antibody therapy trial from the Indianapolis-based pharmaceutical company. Lilly is testing another antibody treatment called LY-COV555 that the company developed with AbCellera.

Junshi Biosciences is leading development in greater China, according to Lilly, and Eli Lilly has exclusive rights to it in the rest of the world.

There are several other companies trying to create antibody therapies to fight Covid-19, including Regeneron Pharmaceuticals, which has said it expects to begin clinical trials this month.

Antibodies are proteins your body makes in the thousands that naturally fight off infection. To make an antibody therapy, scientists have to sort through thousands of antibodies to determine which work best to neutralize a particular threat.

Typically, drug developers will pick one and then clone it until there are enough monoclonal antibodies to put in a medicine.

Antibody treatments are currently used to treat some cancers, eye problems, chronic and infectious disease. The treatments can be used to treat symptoms or potentially as a protective medicine to prevent infection in vulnerable populations like the elderly or in health care workers.

coronavirus antibody

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Chief Adviser Muhammad Yunus meets Japanese Prime Minister Ishiba Shigeru in Japan on 30 May 2025. Photo: CA Office
    Bangladesh, Japan to sign Economic Partnership Agreement by year-end
  • File photo of BNP BNP Standing Committee Member Amir Khasru Mahmud Chowdhury
    Speaking about country’s problems in foreign trips won’t solve them: Khasru takes jibe at Yunus
  • Representational image. Photo: Collected
    'Heavy to very heavy' rainfall expected across country as land depression weakens further

MOST VIEWED

  • Photo: Courtesy
    New notes featuring historic, archaeological structures of Bangladesh to be circulated from 1 June
  • Two Memoranda of Understanding were signed at the seminar titled “Bangladesh Seminar on Human Resources,” in Tokyo on 29 May 2025. Photo: CA Press Wing
    Japan to recruit 100,000 Bangladeshi workers over next 5 years
  • BAT Bangladesh has to vacate Mohakhali HQ as SC rejects lease appeal
    BAT Bangladesh has to vacate Mohakhali HQ as SC rejects lease appeal
  • Representational Photo: Collected
    Country's all jewellery shops to remain indefinitely closed in protest of VP Reponul's arrest: Bajus
  • Khondoker Rashed Maqsood. File Photo: Collected
    Investors urge removal of BSEC chairman in meeting with CA’s special assistant, submit list of demands
  • Illustration: TBS
    Bangladesh repays $3.5b foreign debt in 10 months of FY25

Related News

  • Children have stronger antibody response to Covid: Study
  • Covid-19 antibody surveys underestimate infections: Study
  • Preliminary results show Chinese Covid-19 vaccine candidate safe
  • Antibody drugs are no cure but seem promising for Covid-19
  • US warns of fraudulent coronavirus antibody tests

Features

Babar Ali, Ikramul Hasan Shakil, and Wasfia Nazreen are leading a bold resurgence in Bangladeshi mountaineering, scaling eight-thousanders like Everest, Annapurna I, and K2. Photos: Collected

Back to 8000 metres: How Bangladesh’s mountaineers emerged from a decade-long pause

10h | Panorama
Photos: Courtesy

Behind the looks: Bangladeshi designers shaping celebrity fashion

12h | Mode
Photo collage of the sailors and their catch. Photos: Shahid Sarkar

Between sky and sea: The thrilling life afloat on a fishing ship

17h | Features
For hundreds of small fishermen living near this delicate area, sustainable fishing is a necessity for their survival. Photo: Syed Zakir Hossain

World Ocean Day: Bangladesh’s ‘Silent Island’ provides a fisheries model for the future

1d | The Big Picture

More Videos from TBS

Six Lakh Sacrificial Animals Ready in Sirajganj for Eid-ul-Adha

Six Lakh Sacrificial Animals Ready in Sirajganj for Eid-ul-Adha

7h | TBS Stories
Six MoUs signed during Chief Advisor's visit to Japan

Six MoUs signed during Chief Advisor's visit to Japan

11h | TBS Today
Record migrant deaths in 2024

Record migrant deaths in 2024

1d | Podcast
Govt likely to trim subsidies in new budget

Govt likely to trim subsidies in new budget

14h | TBS Insight
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net